Janis Weeks

Professor Emerita, Department of Biology
Member, ION

Ph.D. University of California, San Diego
B.S. Massachusetts Institute of Technology

Upcoming Seminar: 4/7/2016

"Using high technology and electrophysiology to combat
ancient parasitic diseases"

jweeks@uoregon.edu
Office: 209 Huestis
Phone: 541-346-4517

 

Research Interests: Technology development for drug screening platforms, including anthelmintic (anti-nematode worm) drugs for human and animal health; nematode neurobiology and genetics; synaptic physiology; neural circuits for behavior; insect neurobiology; tropical infectious and parasitic diseases; research and education capacity building in Africa.

Overview: Traditionally, research in the Weeks lab investigated hormonal regulation of the structure, function and survival of neurons and neural circuits, using methods including electrophysiology, biophysics, genetics, genomics and behavioral analysis. This work focused on an extreme example of natural neural plasticity: insect metamorphosis in the moth, Manduca sexta, and fruit fly, Drosophila melanogaster, when neural circuits are reorganized to accommodate different life stages. Hormones similarly influence the vertebrate nervous system with relevance to human health such as Alzheimer's Disease and stress-induced cognitive decline.  

Since the mid-1990s, Weeks has increasingly been involved with research and education in Africa, and the study of tropical parasitic and infectious diseases. Infection with parasitic nematodes causes chronic, debilitating disease in humans and animals in many resource-limited regions of the world. Existing anthelmintic (anti-nematode) drugs are losing potency due to increasing drug resistance in the parasites, and new drugs are critically needed. Within this context, the Weeks lab turned its focus to the small roundworm, Caenorhabditis elegans, a powerful model organism for biological inquiry. The Weeks lab is using combined microfluidic and electrophysiological platforms developed with Shawn Lockery to accelerate the screening process for new anthelmintic drugs, using C. elegans. The ScreenChip platform is also useful for C. elegans models of human aging and disease. Recently, the Bill & Melinda Gates Foundation funded the successful modification of this technology for use with human parasites such as hookworm (Ancylostoma spp.) and roundworm (Ascaris). In 2011, Weeks and Lockery founded a UO spin-off company, NemaMetrix Inc., to enhance commercialization of these devices.

Weeks has taught in and organized advanced neuroscience courses throughout Africa (e.g., Senegal, Egypt, Kenya, Democratic Republic of Congo, South Africa, Ghana) for graduate and medical students, and neuroscience faculty, under the auspices of the International Brain Research Organization.  A member of the African Studies Program, Weeks performs healthcare fieldwork in Zimbabwe and is a student and performer of Zimbabwean music.  At UO, she teaches courses in global health [“Tropical Diseases in Africa” (Bi309) and “HIV/AIDS in Africa” (CHC434)] and helps direct a global-health-focused study abroad and internship program in Accra, Ghana, for undergraduates.  

RECENT PUBLICATIONS

Microfluidic platform for electrophysiological recordings from host-stage hookworm and Ascaris suum larvae: a new tool for anthelmintic research. Weeks JC, Roberts WM, Robinson KJ, Keaney M, Vermeire JJ, Urban Jr., JF, Lockery SR, Hawdon JM.. International Journal for Parasitology: Drugs and Drug Resistance, in press.

Related Articles

Taming the Boys for Global Good: Contraceptive Strategy to Stop Malaria Transmission.

Molecules. 2020 Jun 16;25(12):

Authors: Choi R, Michaels SA, Onu EC, Hulverson MA, Saha A, Coker ME, Weeks JC, Van Voorhis WC, Ojo KK

Abstract
Transmission of human malaria parasites (Plasmodium spp.) by Anopheles mosquitoes is a continuous process that presents a formidable challenge for effective control of the disease. Infectious gametocytes continue to circulate in humans for up to four weeks after antimalarial drug treatment, permitting prolonged transmission to mosquitoes even after clinical cure. Almost all reported malaria cases are transmitted to humans by mosquitoes, and therefore decreasing the rate of Plasmodium transmission from humans to mosquitoes with novel transmission-blocking remedies would be an important complement to other interventions in reducing malaria incidence.

PMID: 32560085 [PubMed - as supplied by publisher]